KTTA Stock: The Despair Nasal Spray News That Has Pasithea Therapeutics Buyers Ecstatic Now

InvestorPlace – Stock Market News, Inventory Advice & Buying and selling Ideas

Pasithea Therapeutics (NASDAQ:KTTA) inventory is rocketing larger on Tuesday right after introducing esketamine nasal spray to its U.K. choices.

colorful pills and vials sitting on a table representing KTTA Stock.

Supply: Bukhta Yurii / Shutterstock.com

The business is giving the esketamine nasal spray by way of its subsidiary, Pasithea Clinics. This spray is beneath the Spravato identify. The nasal spray is treats people suffering from depression in older people that have been resistant to other treatment options.

Pasithea Therapeutics notes that it’s providing the nasal spray at its Knightsbridge, London area. The enterprise also factors out that only three locations in the U.K. have been accredited to offer this procedure.

Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics, claimed the subsequent in the information launch boosting KTTA inventory up now.

“Major Melancholy is the leading induce of prolonged-phrase incapacity around the globe. Latest treatment plans have minimal

Read more